Literature DB >> 16297157

Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

J M Boulter1, B K Jakobsen.   

Abstract

The recent development of T cell receptor phage display opens up the possibility of engineering human T cell receptors with antibody-like binding properties for cell-surface peptide antigens. In this review we briefly discuss recent developments in molecular targeting of peptide antigens. We then discuss potential clinical applications of engineered high-affinity T cell receptors in autoimmunity and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297157      PMCID: PMC1809535          DOI: 10.1111/j.1365-2249.2005.02929.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  64 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Antibody specific for the peptide.major histocompatibility complex. Is it T cell receptor-like?

Authors:  Tatiana Mareeva; Tatiana Lebedeva; Nadia Anikeeva; Tim Manser; Yuri Sykulev
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

3.  Phage antibodies: filamentous phage displaying antibody variable domains.

Authors:  J McCafferty; A D Griffiths; G Winter; D J Chiswell
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

4.  Functional three-domain single-chain T-cell receptors.

Authors:  S Chung; K W Wucherpfennig; S M Friedman; D A Hafler; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

5.  Development of human anti-murine antibody (HAMA) response in patients.

Authors:  J J Tjandra; L Ramadi; I F McKenzie
Journal:  Immunol Cell Biol       Date:  1990-12       Impact factor: 5.126

6.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

7.  Making antibody fragments using phage display libraries.

Authors:  T Clackson; H R Hoogenboom; A D Griffiths; G Winter
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

8.  Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.

Authors:  Pamela A Davol; Janelle A Smith; Nicola Kouttab; Gerald J Elfenbein; Lawrence G Lum
Journal:  Clin Prostate Cancer       Date:  2004-09

9.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

10.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.

Authors:  G P Smith
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

View more
  9 in total

1.  Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.

Authors:  Stephanie L Goff; Laura A Johnson; Mary A Black; Hui Xu; Zhili Zheng; Cyrille J Cohen; Richard A Morgan; Steven A Rosenberg; Steven A Feldman
Journal:  Cancer Immunol Immunother       Date:  2010-07-14       Impact factor: 6.968

Review 2.  A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors:  Dominic Smethurst
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

3.  CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells.

Authors:  Ian A Myles; Ming Zhao; Glenn Nardone; Lisa R Olano; Jensen D Reckhow; Danial Saleem; Timothy J Break; Michail S Lionakis; Timothy G Myers; Paul J Gardina; Charles H Kirkpatrick; Steven M Holland; Sandip K Datta
Journal:  J Leukoc Biol       Date:  2016-08-11       Impact factor: 4.962

Review 4.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

5.  Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains.

Authors:  Brian G Pierce; Jaafar N Haidar; Yong Yu; Zhiping Weng
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

6.  Engineering higher affinity T cell receptors using a T cell display system.

Authors:  Adam S Chervin; David H Aggen; John M Raseman; David M Kranz
Journal:  J Immunol Methods       Date:  2008-10-12       Impact factor: 2.303

7.  Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation.

Authors:  Omer Dushek; Milos Aleksic; Richard J Wheeler; Hao Zhang; Shaun-Paul Cordoba; Yan-Chun Peng; Ji-Li Chen; Vincenzo Cerundolo; Tao Dong; Daniel Coombs; P Anton van der Merwe
Journal:  Sci Signal       Date:  2011-06-07       Impact factor: 8.192

8.  Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.

Authors:  Elin Lunde; Geir Åge Løset; Bjarne Bogen; Inger Sandlie
Journal:  BMC Biotechnol       Date:  2010-08-24       Impact factor: 2.563

Review 9.  Display technologies: application for the discovery of drug and gene delivery agents.

Authors:  Anna Sergeeva; Mikhail G Kolonin; Jeffrey J Molldrem; Renata Pasqualini; Wadih Arap
Journal:  Adv Drug Deliv Rev       Date:  2006-10-06       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.